Carolien Zeetsen

118 Table 6.3. Pearson and Spearman correlations between patient characteristics and scoring above or below the Montreal Cognitive Assessment (MoCA) cut–off both before (T1) and after (T2) detoxification. MoCA cut–off T1 T2 Sex 0.222* –0.171 Age –0.081 0.000 Number of days used in the past 30 days 0.023 –0.067 Daily GHB dose –0.075 0.109 Number of months of daily use 0.020 –0.093 Number of months of use in the lifetime 0.129 –0.192 GHB exposure score 0.137 0.147 Number of comas experienced 0.979 –0.079 Note: * = p < .05. Table 6.4. Means and standard deviations ( SD ) of the Montreal Cognitive Assessment (MoCA) Domain Scores (MoCA–DS) and Total Score (MoCA–TS), including the number (%) of patients scoring below the cut–off, split per outcome group (non–relapse and relapse) before (T1) and after (T2) detoxification. MoCA–DS (range) T1 Non–relapse Relapse p– value ( n = 28) ( n = 52) Executive & visuospatial functions (0–6) 4.42 (1.14) 4.33 (1.24) .721 Attention (0–6) 5.32 (0.86) 4.83 (1.13) .047* Language (0–5) 4.46 (1.04) 4.37 (1.07) .691 Abstract reasoning (0–2) 1.57 (0.69) 1.65 (0.59) .576 Memory (0–5) 3.61 (1.42) 2.58 (1.55) .005* Orientation (0–6) 5.82 (0.39) 5.85 (0.45) .810 MoCA–TS (0–30) 25.21 (2.91) 23.60 (2.94) .021* n (%) < 25 56.6% 76.9% .030* Note: * = p < .05.